Planet MicroCap Showcase: Toronto 2026
Logotype for BioRem Inc

BioRem (BRM) Planet MicroCap Showcase: Toronto 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for BioRem Inc

Planet MicroCap Showcase: Toronto 2026 summary

28 Oct, 2026

Strategy and positioning

  • Vision centers on designing, distributing and servicing air-emission abatement technologies, shifting from lumpy project construction toward recurring service revenue.

  • Offerings now span biological, physical and chemical technologies, engineering, after-sales service and support; soil applications ended in the late 1990s.

  • Core exposure is critical infrastructure, including wastewater and solid-waste facilities, alongside petrochemical, food and beverage, chemical and semiconductor markets.

  • Complex projects in dense urban areas and jurisdictions with strict, enforced emissions rules are described as highly profitable areas of operation.

Performance and pipeline

  • 2026 was described as a strong year, with momentum expected to continue through 2027; top- and bottom-line growth is outpacing market growth.

  • YTD bookings approached CAD 50m, backlog exceeded CAD 70m and contract retention was 99%+; backlog conversion is a question of timing, per management.

  • Unawarded bids exceeded CAD 100m; the historical North American win rate is 35%-52%, and ~half of the bid pool could be awarded over the next 12-18 months.

  • The active sales funnel exceeded CAD 220m; newer products and services represented ~one-third of revenue and bidding activity.

  • Revenue was ~CAD 25m at the 2025 MicroCap presentation and ~CAD 42m last year; EBITDA nearly doubled over the period. Targets include CAD 50m revenue/CAD 5m bottom line, with a stretch goal of CAD 100m/CAD 10m.

Market outlook

  • North American annual spending on air-emission abatement was estimated at ~CAD 1bn, growing 5%-7%; the estimate includes markets not currently served.

  • Technology applications were described as ~40% physical, 30% chemical and 30% biological; chemical use is declining while biological technologies are growing fastest.

  • Five-year revenue growth was estimated at ~12%, nearly double market growth; EBITDA has grown faster than revenue through COVID, hyperinflation and tariff pressures.

  • Migration, aging infrastructure and community demand for air and water quality support infrastructure investment; budgeting and bidding activity were near record levels.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from BioRem